J

Jounce Therapeutics Inc
F:21J

Watchlist Manager
Jounce Therapeutics Inc
F:21J
Watchlist
Price: 1.71 EUR Market Closed
Market Cap: 89.2m EUR

Operating Margin
Jounce Therapeutics Inc

-63.7%
Current
-71%
Average
-4.7%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-63.7%
=
Operating Profit
-52.2m
/
Revenue
82m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Jounce Therapeutics Inc
F:21J
88.4m EUR
-64%
IL
Can Fite Biopharma Ltd
TASE:CANF
168.5T ILS
-1 487%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
389.8B USD
33%
US
Amgen Inc
NASDAQ:AMGN
175.3B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
153.6B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.2B USD
28%
AU
CSL Ltd
ASX:CSL
84.9B AUD
26%
NL
argenx SE
XBRU:ARGX
42.6B EUR
22%
No Stocks Found

Jounce Therapeutics Inc
Glance View

Market Cap
88.4m EUR
Industry
Biotechnology

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treats cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company is headquartered in Cambridge, Massachusetts and currently employs 137 full-time employees. The company went IPO on 2017-01-26. The firm is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. The firm has developed a suite of integrated technologies that consist of its Translational Science Platform, enabling it to interrogate the cellular and molecular composition of tumors. Its program, JTX-8064, is a humanized IgG4, anti-LILRB2 monoclonal antibody designed to reprogram macrophages. JTX-8064 is being developed for patients with either PD-(L)1-inhibitor resistant or PD-(L)1 inhibitor-sensitive tumors. Vopratelimab is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator (ICOS). Pimivalimab is a clinical-stage anti-PD-1 monoclonal antibody that is being developed primarily for its use in combination with its product candidates.

21J Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-63.7%
=
Operating Profit
-52.2m
/
Revenue
82m
What is the Operating Margin of Jounce Therapeutics Inc?

Based on Jounce Therapeutics Inc's most recent financial statements, the company has Operating Margin of -63.7%.

Back to Top